Low-fiber fruits and vegetables, lean proteins, and foods rich in omega-3 fatty acids tend to be easier on an inflamed gut, ...
In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than ...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to ...
Equillium and Biocon announce positive data from phase 2 study of itolizumab to treat moderate to severe ulcerative colitis: Our Bureau, Bengaluru Friday, February 7, 2025, 10:30 ...
Ulcerative colitis affects daily life, but proper management can help maintain quality of life. Learn how to cope with this ...
Equillium (EQ) and Biocon announced topline results from the Phase 2 study evaluating itolizumab in the treatment of moderate to severe ...
PORTLAND, OR, UNITED STATES, February 7, 2025 /EINPresswire / -- The global ulcerative colitis (UC) market is ex ...
The composite of patient-reported clinical response and endoscopic response was significantly greater in mirikizumab versus ...
Bengaluru: Equillium, Inc., a clinical-stage biotechnology company and Biocon Limited, an innovation-led global ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback